BALAXI PHARMACEUTICALS LIMITED

400 billion

oduct lines. 8 Global Footprint China India Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled pr

6 billion

China India Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled products to customers in Africa Pr

INR 49.36 crore

entral African Republic Successfully completed fund raising exercise through Preferential issue – INR 49.36 crore Capex plans – Project initiated for our first Pharma Formulation manufacturing facility in Hydera

39%

traction in top line during the quarter but we managed to maintain a healthy gross profit margin of 39%. In the quarter under review, we received 22 new product registrations. As on 30 September, the nu

46.8%

rgin % EBITDA* EBITDA Margin % Profit After Tax* PAT Margin % Earnings Per Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (

29.9%

* EBITDA Margin % Profit After Tax* PAT Margin % Earnings Per Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 b

26.4%

in % Profit After Tax* PAT Margin % Earnings Per Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1

41.7%

x* PAT Margin % Earnings Per Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1280 bps (6.8%) +850

17.1%

% Earnings Per Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1280 bps (6.8%) +850 bps (0.3%)

17.9%

er Share (INR) 25.60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1280 bps (6.8%) +850 bps (0.3%) *During the cu

36.6%

60 46.8% 16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1280 bps (6.8%) +850 bps (0.3%) *During the current quarter, unre

29.0%

16.41 29.9% 14.43 26.4% 14.10 36.04 41.7% 14.75 17.1% 15.49 17.9% 14.15 YoY (36.6%) (29.0%) +510 bps +11.2% +1280 bps (6.8%) +850 bps (0.3%) *During the current quarter, unrealised lo

“7 Investment in Manufacturing Facilities Setting up its first pharmaceutical formulation manufacturing unit General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Production from Pharma SEZ unit near Hyderabad by the end of FY25 Historically, Balaxi has successfully executed on its “produce, stock and sell” model.”

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“With the increase in the number of product offerings, we expect to further increase our market share in the countries of our focus.”

“We also plan to launch our operations in new countries in these regions.”

Expansion initiated

1

Expansion initiated

Nicaragua, Ecuador, Chile (Latin America) 855 product registrations in six countries 700+ registrations submitted or in the pipeline Establishing the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-English speaking countries with similar characteristics  Low competitive intensity and potential to establish top-2 position  On-ground feedback mechanism allows deep understanding of demand dynamics  As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management  Established unique ecosystem of 100+ Indian expatriates in operating geographies  Financial security ecosystem for key personnel